CANCER:

Lung Cancer

ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: A1 - Approval Future Oncol - 2 days (New A1)	alectinib Sensitive: A1 - Approval Future Oncol - 2 days - (New C3)
FAT1 mutation FAT1 mutation	Non Small Cell Lung Cancer NSCLC	FAT1 mutation FAT1 mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials NPJ Precis Oncol - 2 days (New C3)	Immunotherapy Sensitive: C3 – Early Trials NPJ Precis Oncol - 2 days - (New C3)
Chr del(9)(p21.3) Chr del(9)(p21.3)	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Chr del(9)(p21.3) Chr del(9)(p21.3)	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Resistant: C3 – Early Trials NPJ Precis Oncol - 2 days (New C3)	Immunotherapy Resistant: C3 – Early Trials NPJ Precis Oncol - 2 days - (New C3)
MET amplification + MET exon 14 mutation + EGFR exon 20 insertion MET amplification + MET exon 14 mutation + EGFR exon 20 insertion	Lung Adenocarcinoma LUAD	MET amplification + MET exon 14 mutation + EGFR exon 20 insertion MET amplification + MET exon 14 mutation + EGFR exon 20 insertion	Lung Adenocarcinoma LUAD	crizotinib Sensitive: C4 – Case Studies BMC Med Genomics - 2 days (New C4)	crizotinib Sensitive: C4 – Case Studies BMC Med Genomics - 2 days - (New C4)
NF2 deletion NF2 deletion	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	NF2 deletion NF2 deletion	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	IK-930 Sensitive: B - Late Trials Ikena Oncology Press Release - 3 days (New B)	IK-930 Sensitive: B - Late Trials Ikena Oncology Press Release - 3 days - (New B)
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	capmatinib Sensitive: A1 - Approval Novartis Press Release - 3 days (New A1)	capmatinib Sensitive: A1 - Approval Novartis Press Release - 3 days - (New A1)
EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: C2 – Inclusion Criteria Lung Cancer - 3 days (New C2)	osimertinib Sensitive: C2 – Inclusion Criteria Lung Cancer - 3 days - (New C3)
TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: B - Late Trials Lung Cancer - 5 days (New B)	Immunotherapy Sensitive: B - Late Trials Lung Cancer - 5 days - (New C3)
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	pemetrexed Sensitive: C2 – Inclusion Criteria Int J Clin Oncol - 5 days (New C2)	pemetrexed Sensitive: C2 – Inclusion Criteria Int J Clin Oncol - 5 days - (New C3)
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Lung Cancer - 5 days (New C3)	Immunotherapy Sensitive: C3 – Early Trials Lung Cancer - 5 days - (New C3)
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Resistant: C3 – Early Trials Lung Cancer - 5 days (New C3)	Immunotherapy Resistant: C3 – Early Trials Lung Cancer - 5 days - (New C3)
KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Resistant: C3 – Early Trials Lung Cancer - 5 days (New C3)	Immunotherapy Resistant: C3 – Early Trials Lung Cancer - 5 days - (New C3)
STK11 mutation + KEAP1 mutation + KRAS G12C STK11 mutation + KEAP1 mutation + KRAS G12C	Non Small Cell Lung Cancer NSCLC	STK11 mutation + KEAP1 mutation + KRAS G12C STK11 mutation + KEAP1 mutation + KRAS G12C	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Lung Cancer - 5 days (New C3)	Immunotherapy Sensitive: C3 – Early Trials Lung Cancer - 5 days - (New C3)
KDR expression KDR expression	Non Small Cell Lung Cancer NSCLC	KDR expression KDR expression	Non Small Cell Lung Cancer NSCLC	Immunotherapy Resistant: C3 – Early Trials Cancer Sci - 5 days (New C3)	Immunotherapy Resistant: C3 – Early Trials Cancer Sci - 5 days - (New C3)
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A2 - Guideline Future Oncol - 1 week (New A2)	osimertinib Sensitive: A2 - Guideline Future Oncol - 1 week - (New C3)
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval BMC Cancer - 1 week (New A1)	osimertinib Sensitive: A1 - Approval BMC Cancer - 1 week - (New C3)
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval Onco Targets Ther - 1 week (New A1)	osimertinib Sensitive: A1 - Approval Onco Targets Ther - 1 week - (New C4)
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval Front Pharmacol - 1 week (New A1)	dacomitinib Sensitive: A1 - Approval Front Pharmacol - 1 week - (New C3)
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval Onco Targets Ther - 1 week (New A1)	erlotinib Sensitive: A1 - Approval Onco Targets Ther - 1 week - (New C4)
EGFR exon 19 deletion + PD-L1 expression EGFR exon 19 deletion + PD-L1 expression	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion + PD-L1 expression EGFR exon 19 deletion + PD-L1 expression	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: C3 – Early Trials Sci Rep - 1 week (New C3)	osimertinib Sensitive: C3 – Early Trials Sci Rep - 1 week - (New C3)
FOXM1 rs3742076_G FOXM1 rs3742076_G	Non Small Cell Lung Cancer NSCLC	FOXM1 rs3742076_G FOXM1 rs3742076_G	Non Small Cell Lung Cancer NSCLC	gefitinib Resistant: C3 – Early Trials Clin Cancer Res - 1 week (New C3)	gefitinib Resistant: C3 – Early Trials Clin Cancer Res - 1 week - (New C3)
EML4-ALK variant 2 EML4-ALK variant 2	Lung Adenocarcinoma LUAD	EML4-ALK variant 2 EML4-ALK variant 2	Lung Adenocarcinoma LUAD	ALK inhibitor Sensitive: C4 – Case Studies Springer - 1 week (New C4)	ALK inhibitor Sensitive: C4 – Case Studies Springer - 1 week - (New C4)
CFTR expression CFTR expression	Lung Adenocarcinoma LUAD	CFTR expression CFTR expression	Lung Adenocarcinoma LUAD	CFTR potentiator Sensitive: D – Preclinical J Cancer Res Clin Oncol - 1 week (New D)	CFTR potentiator Sensitive: D – Preclinical J Cancer Res Clin Oncol - 1 week - (New D)
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	sugemalimab Sensitive: A1 - Approval CStone Pharma Press Release - 2 weeks (New A1)	sugemalimab Sensitive: A1 - Approval CStone Pharma Press Release - 2 weeks - (New A1)
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Sensitive: B - Late Trials Cancer Med - 2 weeks (New B)	EGFR inhibitor Sensitive: B - Late Trials Cancer Med - 2 weeks - (New C3)
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	TPX-0005 Sensitive: B - Late Trials Zai Lab Press Release - 2 weeks (New B)	TPX-0005 Sensitive: B - Late Trials Zai Lab Press Release - 2 weeks - (New C3)
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval Thorac Cancer - 2 weeks (New A1)	afatinib Sensitive: A1 - Approval Thorac Cancer - 2 weeks - (New C3)
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval Thorac Cancer - 2 weeks (New A1)	afatinib Sensitive: A1 - Approval Thorac Cancer - 2 weeks - (New C3)
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval Roche Press Release - 2 weeks (New A1)	atezolizumab Sensitive: A1 - Approval Roche Press Release - 2 weeks - (New A1)
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline Oncology - 2 weeks (New A2)	crizotinib Sensitive: A2 - Guideline Oncology - 2 weeks - (New C3)
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: B - Late Trials Thorac Cancer - 2 weeks (New B)	afatinib Sensitive: B - Late Trials Thorac Cancer - 2 weeks - (New C3)
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	MRTX849 Sensitive: B - Late Trials Cancer Discov - 2 weeks (New B)	MRTX849 Sensitive: B - Late Trials Cancer Discov - 2 weeks - (New C3)
KDM5C mutation KDM5C mutation	Non Small Cell Lung Cancer NSCLC	KDM5C mutation KDM5C mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Cancers (Basel) - 2 weeks (New C3)	Immunotherapy Sensitive: C3 – Early Trials Cancers (Basel) - 2 weeks - (New C3)
EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials Clin Transl Oncol - 2 weeks (New C3)	afatinib Sensitive: C3 – Early Trials Clin Transl Oncol - 2 weeks - (New D)
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD1 inhibitor Sensitive: C3 – Early Trials Pharmacoepidemiol Drug Saf - 2 weeks (New C3)	PD1 inhibitor Sensitive: C3 – Early Trials Pharmacoepidemiol Drug Saf - 2 weeks - (New C3)
KMT2C mutation KMT2C mutation	Non Small Cell Lung Cancer NSCLC	KMT2C mutation KMT2C mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Cancers (Basel) - 2 weeks (New C3)	Immunotherapy Sensitive: C3 – Early Trials Cancers (Basel) - 2 weeks - (New C3)
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials Pharmacoepidemiol Drug Saf - 2 weeks (New C3)	PD-L1 inhibitor Sensitive: C3 – Early Trials Pharmacoepidemiol Drug Saf - 2 weeks - (New C3)
KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	KRAS mutation KRAS mutation	Non Small Cell Lung Cancer NSCLC	durvalumab Resistant: C3 – Early Trials JAMA Netw Open - 2 weeks (New C3)	durvalumab Resistant: C3 – Early Trials JAMA Netw Open - 2 weeks - (New C3)
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	durvalumab Resistant: C3 – Early Trials JAMA Netw Open - 2 weeks (New C3)	durvalumab Resistant: C3 – Early Trials JAMA Netw Open - 2 weeks - (New C3)
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: C3 – Early Trials JAMA Netw Open - 2 weeks (New C3)	durvalumab Sensitive: C3 – Early Trials JAMA Netw Open - 2 weeks - (New C3)
KMT2C mutation + BCOR mutation + KDM5C mutation KMT2C mutation + BCOR mutation + KDM5C mutation	Non Small Cell Lung Cancer NSCLC	KMT2C mutation + BCOR mutation + KDM5C mutation KMT2C mutation + BCOR mutation + KDM5C mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Cancers (Basel) - 2 weeks (New C3)	Immunotherapy Sensitive: C3 – Early Trials Cancers (Basel) - 2 weeks - (New C3)
BCOR mutation BCOR mutation	Non Small Cell Lung Cancer NSCLC	BCOR mutation BCOR mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Cancers (Basel) - 2 weeks (New C3)	Immunotherapy Sensitive: C3 – Early Trials Cancers (Basel) - 2 weeks - (New C3)
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	pembrolizumab + SNK01 Sensitive: C3 – Early Trials Thorac Cancer - 2 weeks (New C3)	pembrolizumab + SNK01 Sensitive: C3 – Early Trials Thorac Cancer - 2 weeks - (New C3)
NTRK2 fusion NTRK2 fusion	Non Small Cell Lung Cancer NSCLC	NTRK2 fusion NTRK2 fusion	Non Small Cell Lung Cancer NSCLC	durvalumab Resistant: C3 – Early Trials JAMA Netw Open - 2 weeks (New C3)	durvalumab Resistant: C3 – Early Trials JAMA Netw Open - 2 weeks - (New C3)
EML4-ALK fusion EML4-ALK fusion	Non Small Cell Lung Cancer NSCLC	EML4-ALK fusion EML4-ALK fusion	Non Small Cell Lung Cancer NSCLC	durvalumab Resistant: C3 – Early Trials JAMA Netw Open - 2 weeks (New C3)	durvalumab Resistant: C3 – Early Trials JAMA Netw Open - 2 weeks - (New C3)
HER-2 exon 20 insertion HER-2 exon 20 insertion	Non Small Cell Lung Cancer NSCLC	HER-2 exon 20 insertion HER-2 exon 20 insertion	Non Small Cell Lung Cancer NSCLC	durvalumab Resistant: C3 – Early Trials JAMA Netw Open - 2 weeks (New C3)	durvalumab Resistant: C3 – Early Trials JAMA Netw Open - 2 weeks - (New C3)
EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	durvalumab Resistant: C3 – Early Trials JAMA Netw Open - 2 weeks (New C3)	durvalumab Resistant: C3 – Early Trials JAMA Netw Open - 2 weeks - (New C3)
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	durvalumab Resistant: C3 – Early Trials JAMA Netw Open - 2 weeks (New C3)	durvalumab Resistant: C3 – Early Trials JAMA Netw Open - 2 weeks - (New C3)
KMT2C mutation + BCOR mutation + KDM5C mutation + TMB-H KMT2C mutation + BCOR mutation + KDM5C mutation + TMB-H	Non Small Cell Lung Cancer NSCLC	KMT2C mutation + BCOR mutation + KDM5C mutation + TMB-H KMT2C mutation + BCOR mutation + KDM5C mutation + TMB-H	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Cancers (Basel) - 2 weeks (New C3)	Immunotherapy Sensitive: C3 – Early Trials Cancers (Basel) - 2 weeks - (New C3)
KMT2C mutation + BCOR mutation + KDM5C mutation + PD-L1 expression KMT2C mutation + BCOR mutation + KDM5C mutation + PD-L1 expression	Non Small Cell Lung Cancer NSCLC	KMT2C mutation + BCOR mutation + KDM5C mutation + PD-L1 expression KMT2C mutation + BCOR mutation + KDM5C mutation + PD-L1 expression	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Cancers (Basel) - 2 weeks (New C3)	Immunotherapy Sensitive: C3 – Early Trials Cancers (Basel) - 2 weeks - (New C3)
EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	osimertinib Sensitive: C4 – Case Studies Clin Transl Oncol - 2 weeks (New C4)	osimertinib Sensitive: C4 – Case Studies Clin Transl Oncol - 2 weeks - (New D)
FGFR2-ERC1 fusion FGFR2-ERC1 fusion	Lung Adenocarcinoma LUAD	FGFR2-ERC1 fusion FGFR2-ERC1 fusion	Lung Adenocarcinoma LUAD	anlotinib Sensitive: C4 – Case Studies Onco Targets Ther - 2 weeks (New C4)	anlotinib Sensitive: C4 – Case Studies Onco Targets Ther - 2 weeks - (New C4)
EGFR exon 19 deletion + EGFR L861Q EGFR exon 19 deletion + EGFR L861Q	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion + EGFR L861Q EGFR exon 19 deletion + EGFR L861Q	Lung Adenocarcinoma LUAD	erlotinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks (New D)	erlotinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks - (New D)
EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	erlotinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks (New D)	erlotinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks - (New D)
EGFR exon 19 deletion + EGFR L861Q EGFR exon 19 deletion + EGFR L861Q	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion + EGFR L861Q EGFR exon 19 deletion + EGFR L861Q	Lung Adenocarcinoma LUAD	afatinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks (New D)	afatinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks - (New D)
EGFR exon 19 deletion + EGFR L861Q EGFR exon 19 deletion + EGFR L861Q	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion + EGFR L861Q EGFR exon 19 deletion + EGFR L861Q	Lung Adenocarcinoma LUAD	osimertinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks (New D)	osimertinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks - (New D)
EGFR exon 19 deletion + EGFR L861Q EGFR exon 19 deletion + EGFR L861Q	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion + EGFR L861Q EGFR exon 19 deletion + EGFR L861Q	Lung Adenocarcinoma LUAD	dacomitinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks (New D)	dacomitinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks - (New D)
EGFR exon 19 deletion + EGFR L861Q EGFR exon 19 deletion + EGFR L861Q	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion + EGFR L861Q EGFR exon 19 deletion + EGFR L861Q	Lung Adenocarcinoma LUAD	icotinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks (New D)	icotinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks - (New D)
EGFR exon 19 deletion + EGFR L861Q EGFR exon 19 deletion + EGFR L861Q	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion + EGFR L861Q EGFR exon 19 deletion + EGFR L861Q	Lung Adenocarcinoma LUAD	gefitinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks (New D)	gefitinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks - (New D)
EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	gefitinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks (New D)	gefitinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks - (New D)
EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	icotinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks (New D)	icotinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks - (New D)
EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	dacomitinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks (New D)	dacomitinib Sensitive: D – Preclinical Clin Transl Oncol - 2 weeks - (New D)
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval BMC Cancer - 3 weeks (New A1)	osimertinib Sensitive: A1 - Approval BMC Cancer - 3 weeks - (New C3)
HER-2 mutation HER-2 mutation	Non Small Cell Lung Cancer NSCLC	HER-2 mutation HER-2 mutation	Non Small Cell Lung Cancer NSCLC	afatinib Resistant: A2 - Guideline Target Oncol - 3 weeks (New A2)	afatinib Resistant: A2 - Guideline Target Oncol - 3 weeks - (New C4)
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	furmonertinib Sensitive: B - Late Trials Lancet Respir Med - 3 weeks (New B)	furmonertinib Sensitive: B - Late Trials Lancet Respir Med - 3 weeks - (New B)
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	furmonertinib Sensitive: B - Late Trials Lancet Respir Med - 3 weeks (New B)	furmonertinib Sensitive: B - Late Trials Lancet Respir Med - 3 weeks - (New B)
NTRK2 fusion NTRK2 fusion	Lung Cancer Lung Cancer	NTRK2 fusion NTRK2 fusion	Lung Cancer Lung Cancer	larotrectinib Sensitive: C1 - Off-label J Clin Oncol - 3 weeks (New C1)	larotrectinib Sensitive: C1 - Off-label J Clin Oncol - 3 weeks - (New C3)
NTRK1 fusion NTRK1 fusion	Lung Cancer Lung Cancer	NTRK1 fusion NTRK1 fusion	Lung Cancer Lung Cancer	larotrectinib Sensitive: C1 - Off-label J Clin Oncol - 3 weeks (New C1)	larotrectinib Sensitive: C1 - Off-label J Clin Oncol - 3 weeks - (New C3)
NTRK3 fusion NTRK3 fusion	Lung Cancer Lung Cancer	NTRK3 fusion NTRK3 fusion	Lung Cancer Lung Cancer	larotrectinib Sensitive: C1 - Off-label J Clin Oncol - 3 weeks (New C1)	larotrectinib Sensitive: C1 - Off-label J Clin Oncol - 3 weeks - (New C3)
EGFR T790M EGFR T790M	Lung Cancer Lung Cancer	EGFR T790M EGFR T790M	Lung Cancer Lung Cancer	osimertinib Sensitive: C1 - Off-label Transl Oncol - 3 weeks (New C1)	osimertinib Sensitive: C1 - Off-label Transl Oncol - 3 weeks - (New D)
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	bevacizumab Sensitive: C2 – Inclusion Criteria Cancer Manag Res - 3 weeks (New C2)	bevacizumab Sensitive: C2 – Inclusion Criteria Cancer Manag Res - 3 weeks - (New C3)
MET negative + EGFR mutation MET negative + EGFR mutation	Non Small Cell Lung Cancer NSCLC	MET negative + EGFR mutation MET negative + EGFR mutation	Non Small Cell Lung Cancer NSCLC	osimertinib + selumetinib Sensitive: C3 – Early Trials Clin Cancer Res - 3 weeks (New C3)	osimertinib + selumetinib Sensitive: C3 – Early Trials Clin Cancer Res - 3 weeks - (New C3)
ABCB6 expression ABCB6 expression	Non Small Cell Lung Cancer NSCLC	ABCB6 expression ABCB6 expression	Non Small Cell Lung Cancer NSCLC	gemcitabine Resistant: C3 – Early Trials Cell Mol Life Sci - 3 weeks (New C3)	gemcitabine Resistant: C3 – Early Trials Cell Mol Life Sci - 3 weeks - (New C3)
CD74-ROS1 fusion CD74-ROS1 fusion	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	CD74-ROS1 fusion CD74-ROS1 fusion	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	crizotinib Sensitive: C4 – Case Studies J Cancer Res Clin Oncol - 3 weeks (New C4)	crizotinib Sensitive: C4 – Case Studies J Cancer Res Clin Oncol - 3 weeks - (New C4)
EGFR exon 19 deletion + EGFR G724S EGFR exon 19 deletion + EGFR G724S	Lung Cancer Lung Cancer	EGFR exon 19 deletion + EGFR G724S EGFR exon 19 deletion + EGFR G724S	Lung Cancer Lung Cancer	dacomitinib Sensitive: C4 – Case Studies Invest New Drugs - 3 weeks (New C4)	dacomitinib Sensitive: C4 – Case Studies Invest New Drugs - 3 weeks - (New C4)
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	ramucirumab Sensitive: A1 - Approval	ramucirumab Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	lorlatinib Sensitive: A1 - Approval	lorlatinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval	gefitinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: A1 - Approval	durvalumab Sensitive: A1 - Approval
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval	nivolumab + ipilimumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A1 - Approval	brigatinib Sensitive: A1 - Approval
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	sotorasib Sensitive: A1 - Approval	sotorasib Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A1 - Approval	nivolumab + ipilimumab Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A1 - Approval	brigatinib Sensitive: A1 - Approval
ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	entrectinib Sensitive: A1 - Approval	entrectinib Sensitive: A1 - Approval
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	tepotinib Sensitive: A1 - Approval	tepotinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	bevacizumab Sensitive: A1 - Approval	bevacizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A1 - Approval	nivolumab + ipilimumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval	dacomitinib Sensitive: A1 - Approval
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval	durvalumab Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	lazertinib Sensitive: A1 - Approval	lazertinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval	dacomitinib Sensitive: A1 - Approval
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	cemiplimab Sensitive: A1 - Approval	cemiplimab Sensitive: A1 - Approval
RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	pralsetinib Sensitive: A1 - Approval	pralsetinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	cisplatin + pemetrexed Sensitive: A1 - Approval	cisplatin + pemetrexed Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval	gefitinib Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval	gefitinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	pemetrexed Sensitive: A1 - Approval	pemetrexed Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	cisplatin Sensitive: A1 - Approval	cisplatin Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A1 - Approval	crizotinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A1 - Approval	crizotinib Sensitive: A1 - Approval
RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	selpercatinib Sensitive: A1 - Approval	selpercatinib Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	mobocertinib Sensitive: A1 - Approval	mobocertinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: A1 - Approval	durvalumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval	erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	tislelizumab Sensitive: A1 - Approval	tislelizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	DP Sensitive: A1 - Approval	DP Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ensartinib Sensitive: A1 - Approval	ensartinib Sensitive: A1 - Approval
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	savolitinib Sensitive: A1 - Approval	savolitinib Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	bevacizumab + atezolizumab Sensitive: A1 - Approval	bevacizumab + atezolizumab Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval	erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval	bevacizumab + atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval	Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	topotecan Sensitive: A1 - Approval	topotecan Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab Sensitive: A1 - Approval	bevacizumab Sensitive: A1 - Approval
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	cisplatin + pemetrexed Sensitive: A1 - Approval	cisplatin + pemetrexed Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	pemetrexed Sensitive: A1 - Approval	pemetrexed Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval	cisplatin + pemetrexed Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	carboplatin + albumin-bound paclitaxel Sensitive: A1 - Approval	carboplatin + albumin-bound paclitaxel Sensitive: A1 - Approval
No biomarker No biomarker	Lung Adenocarcinoma LUAD	No biomarker No biomarker	Lung Adenocarcinoma LUAD	nintedanib Sensitive: A1 - Approval	nintedanib Sensitive: A1 - Approval
EGFR expression EGFR expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	EGFR expression EGFR expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	necitumumab Sensitive: A1 - Approval	necitumumab Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	bevacizumab + atezolizumab Sensitive: A1 - Approval	bevacizumab + atezolizumab Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	trametinib + dabrafenib Sensitive: A1 - Approval	trametinib + dabrafenib Sensitive: A1 - Approval
No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	No biomarker No biomarker	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	pemetrexed Sensitive: A1 - Approval	pemetrexed Sensitive: A1 - Approval
No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	No biomarker No biomarker	Small Cell Lung Cancer Small Cell Lung Cancer	lurbinectedin Sensitive: A1 - Approval	lurbinectedin Sensitive: A1 - Approval
EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	amivantamab-vmjw Sensitive: A1 - Approval	amivantamab-vmjw Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	docetaxel Sensitive: A1 - Approval	docetaxel Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval	erlotinib Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ceritinib Sensitive: A1 - Approval	ceritinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	aumolertinib Sensitive: A1 - Approval	aumolertinib Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + erlotinib Sensitive: A1 - Approval	bevacizumab + erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	sintilimab Sensitive: A1 - Approval	sintilimab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A1 - Approval	erlotinib + ramucirumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	erlotinib + Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval	erlotinib + Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
ALK mutation ALK mutation	Non Small Cell Lung Cancer NSCLC	ALK mutation ALK mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A1 - Approval	erlotinib + ramucirumab Sensitive: A1 - Approval
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	entrectinib Sensitive: A1 - Approval	entrectinib Sensitive: A1 - Approval
BRAF V600 BRAF V600	Non Small Cell Lung Cancer NSCLC	BRAF V600 BRAF V600	Non Small Cell Lung Cancer NSCLC	trametinib + dabrafenib Sensitive: A1 - Approval	trametinib + dabrafenib Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	afatinib Sensitive: A1 - Approval	afatinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	tislelizumab Sensitive: A1 - Approval	tislelizumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
ALK mutation ALK mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ALK mutation ALK mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	cemiplimab Sensitive: A1 - Approval	cemiplimab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	sintilimab Sensitive: A1 - Approval	sintilimab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
EGFR mutation + ALK negative + TMB-H EGFR mutation + ALK negative + TMB-H	Non Small Cell Lung Cancer NSCLC	EGFR mutation + ALK negative + TMB-H EGFR mutation + ALK negative + TMB-H	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline	crizotinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	dabrafenib Sensitive: A2 - Guideline	dabrafenib Sensitive: A2 - Guideline
ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	ceritinib Sensitive: A2 - Guideline	ceritinib Sensitive: A2 - Guideline

Lung Cancer

Associations(3038)

Associations
(3038)